"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.
"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.
复制标题
DOI:
10.1371/journal.pone.0279073
复制
发表时间:
2022
期刊:
影响因子:
3.7
通讯作者:
Michalak, Erin
中科院分区:
文献类型:
--
作者:
DellaCrosse, Meghan;Pleet, Mollie;Morton, Emma;Ashtari, Amir;Sakai, Kimberly;Woolley, Josh;Michalak, Erin
People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have excluded people with BD as a precaution against possible adverse effects (e.g., mania). Our study centered the experiences of adults living with BD who consumed psilocybin-containing mushrooms, and aimed to (1) understand its subjective impacts on BD symptoms, (2) deepen understanding of Phase I survey results, and (3) elucidate specific contextual factors associated with adverse reactions in naturalistic settings. Following an international survey (Phase I), follow-up interviews were conducted with 15 respondents (Phase II) to further understand psilocybin use among adults with BD. As part of a larger mixed-methods explanatory sequential design study, reflexive thematic analysis was used to elaborate findings. Three major themes containing sub-themes were developed. (1) Mental Health Improvements: (1.1) decreased impact and severity of depression, (1.2) increased emotion processing, (1.3) development of new perspectives, and (1.4) greater relaxation and sleep. (2) Undesired Mental Health Impacts: (2.1) changes in sleep, (2.2) increased mania severity, (2.3) hospitalization, and (2.4) distressing sensory experiences. (3) Salient Contextual Factors for psilocybin use included: (3.1) poly-substance use and psilocybin dose, (3.2) solo versus social experiences, and (3.3) pre-psilocybin sleep deprivation. Our findings demonstrate both benefits and risks of psilocybin use in this population. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted.
登录
查看更多内容
影响因子:
25.8
作者:
Davis AK;Barrett FS;May DG;Cosimano MP;Sepeda ND;Johnson MW;Finan PH;Griffiths RR
通讯作者:
Griffiths RR
影响因子:
4.1
作者:
Carhart-Harris, Robin L.;Roseman, Leor;Kaelen, Mendel
通讯作者:
Kaelen, Mendel
影响因子:
5.4
作者:
Adida, Marc;Clark, Luke;Goodwin, Guy M.
通讯作者:
Goodwin, Guy M.
影响因子:
3.4
作者:
Carhart-Harris RL;Bolstridge M;Day CMJ;Rucker J;Watts R;Erritzoe DE;Kaelen M;Giribaldi B;Bloomfield M;Pilling S;Rickard JA;Forbes B;Feilding A;Taylor D;Curran HV;Nutt DJ
通讯作者:
Nutt DJ
影响因子:
1.7
作者:
Agin-Liebes, Gabrielle;Ekman, Eve;Woolley, Josh
通讯作者:
Woolley, Josh